Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database.

Date publication

mars 2026

Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric , Pr PETIT Thierry

Tous les auteurs :
Le Bars S, Guerin-Charbonnel C, Martin E, Thomas QD, Costaz H, Pomel C, Marchal F, Narducci F, Gouy S, Laas E, Rossi L, Lambaudie E, Rouzier R, Petit T, Gladieff L, De La Motte Rouge T, Bosquet L, Colombo PE, Classe JM, Loaec C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42013623

Résumé

Benefits on survival of retroperitoneal lymph node (LN) dissection during cytoreductive surgery (CRS) for epithelial ovarian cancer are debated. However, LN involvement may be a prognostic factor especially in case of high-grade serous ovarian cancer (HGSOC).

Mots clés

Advanced high-grade serous ovarian carcinoma, Cytoreductive surgery, Lymph node involvement ratio, Prognosis, Retroperitoneal lymph node dissection, Survival

Référence

Eur J Surg Oncol. 2026 03 25;52(6):111768